Organ Chip Partnerships Altis is pursuing integrated organ-system collaboration by combining RepliGut Planar with liver-on-a-chip capabilities through a CN Bio partnership to create a multi-organ microphysiological system. This presents sales opportunities to offer co-developed gut-liver solutions to pharma as a bundled platform for ADME and oral exposure studies.

Gut Liver ADME There is a clear path to monetize ADME and safety screening using next-generation gut-liver in vitro models and inflammation screening services. This enables high-value readouts such as metabolism, disposition, and toxicity, creating demand for contract research services and model licenses.

Sustainability Advantage The human-derived RepliGut models support reduced animal testing and align with regulatory and ESG-driven goals, making Altis attractive to pharma companies pursuing 3Rs compliance and safer preclinical data, which can drive renewals and new collaborations.

Market Credibility Altis has established credibility with major pharma and CRO customers through donor-derived intestinal models and a track record of platform-based collaborations, creating opportunities to win large accounts and expand contracts with existing partners.

Service Expansion Existing services like RepliGut InflammaScreen and other contract research offerings can be scaled into repeatable bundles, with potential for ongoing programs and cross-sell across gut, inflammation, and gut-liver testing workflows.